Levosimendan improves renal function in acute decompensated heart failure: Possible underlying mechanisms

European Journal of Heart Failure

Volumn 16, Issue 3, 2014, Pages 281-288

  Fedele, Francesco ^a   Bruno, Noemi ^a   Brasolin, Bruno ^a   Caira, Carmen ^a   D'Ambrosi, Alessandra ^a   Mancone, Massimo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Heart failure; Kidney; Levosimendan; Regional blood flow

Indexed keywords

CREATININE; CYSTATIN C; LEVOSIMENDAN; PLACEBO;

AGED; ARTICLE; CARDIORENAL SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEART HEMODYNAMICS; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MALE; MODERATE RENAL IMPAIRMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM BLOOD LEVEL; SODIUM EXCRETION; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; URINE VOLUME;

HEART FAILURE; KIDNEY; LEVOSIMENDAN; REGIONAL BLOOD FLOW;

AGED; CARDIO-RENAL SYNDROME; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HEMODYNAMICS; HUMANS; HYDRAZONES; KIDNEY; MALE; PYRIDAZINES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84896921309     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.9     Document Type: Article

References (32)

1. Opasich C, Russo A, Mingrone R, Zambelli M, Tavazzi L. Intravenous inotropic agents in the intensive therapy unit: do they really make a difference? Eur J Heart Fail 2000;2:7-11.
2. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, De Zeeuw D, Pocock S, Van Veldhuisen DJ. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006;113:671-678.
3. Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008;34:957-962.
4. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur J Heart Fail 2012;14:803-869.
5. Zafrir B, Amir O. Beta blocker therapy, decompensated heart failure, and inotropic interactions: current perspectives. Isr Med Assoc J 2012;14:184-189.
6. Bergh CH, Andersson B, Dahlström U, Forfang K, Kivikko M, Sarapohja T, Ullman B, Wikström G. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail 2010;12:404-410.
7. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L. Efficacy and safety of intravenous levosimendan compared with dobutamina in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet 2002;360:196-202.
8. Silva-Cardoso J, Ferreira J, Oliveira-Soares A, Martins-de-Campos J, Fonseca C, Lousada N, Ilídio-Moreira J, Rabaçal C, Damasceno A, Amorim S, Seabra-Gomes R, Ferreira R, Abreu-Lima C. Effectiveness and safety of levosimendan in clinical practice. Rev Port Cardiol 2009;28:143-154.
9. Zemljic G, Bunc M, Yazdanbakhsh AP, Vrtovec B. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. J Card Fail 2007;13:417-421.
10. Yilmaz MB, Yalta K, Yontar C, Karadas F, Erdem A, Turgut OO, Yilmaz A, Tandogan I. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther 2007;21:431-435.
11. Damman K, Navis G, Smilde TDJ. Decreased cardiac output, venous congestion, and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007;9:872-878.
12. Tiwari MM, Brock RW, Megyesi JK, Kaushal GP, Mayeux PR. Disruption of renal peritubular blood flow in lipopolysaccharide-induced renal failure. Role of nitric oxide and caspases. Am J Physiol Renal Physiol 2005;289:F1324-F1332.
13. Wang Le F, Patel M, Razavi HM, Weicker S, Joseph MG, McCormack DG, Mehta S. Role of inducible nitric oxide synthase in pulmonary microvascular protein leak in murine sepsis. Am J Respir Crit Care Med 2002;165:1634-1639.
14. Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol 2006;47:1-8.
15. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikäinen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002;40:465-471.
16. Pataricza J, Krassoi I, Hohn J, Kun A, Papp JG. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 2003;17:115-121.
17. Kivikko M, Lehtonen L. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Curr Pharm Des 2005;11:435-455.
18. Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendanin patients with congestive heart failure. Eur J Heart Fail 2007;9:75-82.
19. McLean AS, Huang SJ, Nalos M, Ting I. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide. J Cardiovasc Pharmacol 2005;46:830-835.
20. Husebye T, Eritsland J, Muller C, Sandvik L, Arnesen H, Seljeflot I, Mangschau A, Bjørnerheim R, Andersen GØ. Levosimendan in acute heart failure following primary percutaneous coronary interventiontreated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. Eur J Heart Fail 2013;15:565-572.
21. Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ, Thakkar R, Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 2013;1:103-111.
22. Haikala H, Pollesello P. Calcium sensitivity enhancers. IDrugs 2000;3:1199-1205.
23. Poelzl G, Zwick RH, Grander W, Metzler B, Jonetzko P, Frick M, Ulmer H, Pachinger O, Roithinger FX. Safety and effectiveness of levosimendan in patients with predominant right heart failure. Herz 2008;33:368-373.
24. Russ MA, Prondzinsky R, Carter JM, Schlitt A, Ebelt H, Schmidt H, Lemm H, Heinroth K, Soeffker G, Winkler M, Werdan K, Buerke M. Right ventricular function in myocardial infarction complicated by cardiogenic shock: improvement with levosimendan. Crit Care Med 2009;37:3017-3023.
25. Bragadottir G, Redfors B, Ricksten SE. Effects of levosimendan on renal blood flow, glomerular filtration rate, renal oxygen consumption and oxygenation after cardiac surgery: a randomized controlled study. Crit Care Med 2013;41:2328-2335.
26. Lorenz JN, Schnermann J, Brosius FC, Briggs JP, Furspan PB. Intracellular ATP can regulate afferent arteriolar tone via ATP-sensitive K+ channels in the rabbit. J Clin Invest 1992;90:733-740.
27. Damman K, Voors AA. Levosimendan improves renal function in acute decompensated heart failure: cause and clinical application. Cardiovasc Drugs Ther 2007;21:403-404.
28. Faivre V, Kaskos H, Callebert J. Cardiac and renal effects of levosimendan, arginine vasopressin, and norepinephrine in lipopolysaccharide- treated rabbits. Anesthesiology 2005;103:514-521.
29. Pataricza J, Hohn J, Petri A, Balogh A, Papp JG. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol 2000;52:213-217.
30. Paraskevaidis IA, Parissis JT, Kremastinos D. Anti-inflammatory and antiapoptotic effects of levosimendan in decompansated heart failure: a novel mechanism of drug-induced improvement in contractile performance of the failing heart. Curr Med Chem Cardiovasc Hematol Agents 2005;3:243-247.
31. Parissis JT, Farmakis D, Kremastinos DT. Anti-inflammatory effects of levosimendan in decompensated heart failure: impact on weight loss and anemia. Am J Cardiol 2005;95:923-924.
32. Pagel PS, Hettrick DA, Warltier DC. Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br J Pharmacol 1996;119:609-615.